Systematic review with network meta-analysis: Statins and risk of hepatocellular carcinoma

Oncotarget

Volumn 7, Issue 16, 2016, Pages 21753-21762

  Zhou, Yao Yao ^a   Zhu, Gui Qi ^b,c   Wang, Yue ^a   Zheng, Ji Na ^b,c   Ruan, Lu Yi ^b,c   Cheng, Zhang ^b,c   Hu, Bin ^b,c   Fu, Shen Wen ^a   Zheng, Ming Hua ^b,c  

^a Jinhua Municipal Hospital   (China)

^b THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^c WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Indirect comparison; Network meta analysis; Statins

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; INDOLE DERIVATIVE; MONOUNSATURATED FATTY ACID; PYRIDINE DERIVATIVE;

ARTICLE; CANCER PATIENT; DRUG EFFICACY; HUMAN; LIVER CANCER; LIVER CELL CARCINOMA; META ANALYSIS (TOPIC); OBSERVATIONAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; TREATMENT RESPONSE; BAYES THEOREM; CLASSIFICATION; COMBINATION DRUG THERAPY; DRUG EFFECTS; LIVER; LIVER TUMOR; META ANALYSIS; PATHOLOGY;

ATORVASTATIN CALCIUM; BAYES THEOREM; CARCINOMA, HEPATOCELLULAR; DRUG THERAPY, COMBINATION; FATTY ACIDS, MONOUNSATURATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; LIVER; LIVER NEOPLASMS; LOVASTATIN; OBSERVATIONAL STUDIES AS TOPIC; PRAVASTATIN; PYRIDINES; ROSUVASTATIN CALCIUM; SIMVASTATIN; TREATMENT OUTCOME;

EID: 84965056875     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7832     Document Type: Article

References (30)

1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 12:1118-1127.
2. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 9822:1245-1255.
3. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 2005; 9493:1267-1278.
4. Boudreau DM, Yu O, Johnson J. Statin use and cancer risk: a comprehensive review. Expert Opinion on Drug Safety 2010; 4:603-621.
5. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nature Reviews Cancer 2005; 12:930-942.
6. Lonardo A, Loria P. Potential for statins in the chemoprevention and management of hepatocellular carcinoma. J Gastroenterol Hepatol 2012; 11:1654-1664.
7. Kawata S, Yamasaki E, Nagase T, Inui Y, Ito N, Matsuda Y, Inada M, Tamura S, Noda S, Imai Y, Matsuzawa Y. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 2001; 7:886-891.
8. Graf H, Jungst C, Straub G, Dogan S, Hoffmann RT, Jakobs T, Reiser M, Waggershauser T, Helmberger T, Walter A, Walli A, Seidel D, Goke B, et al. Chemoembolization combined with pravastatin improves survival in patients with hepatocellular carcinoma. Digestion 2008; 1:34-38.
9. McGlynn KA, Divine GW, Sahasrabuddhe VV, Engel LS, VanSlooten A, Wells K, Yood MU, Alford SH. Statin use and risk of hepatocellular carcinoma in a U.S. population. Cancer Epidemiology 2014; 5:523-527.
10. Shi M, Zheng H, Nie B, Gong W, Cui X. Statin use and risk of liver cancer: an update meta-analysis. BMJ Open 2014; 9:e5399.
11. Pradelli D, Soranna D, Scotti L, Zambon A, Catapano A, Mancia G, La Vecchia C, Corrao G. Statins and primary liver cancer: a meta-analysis of observational studies. European Journal of Cancer Prevention 2013; 3:229-234.
12. Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 2013; 2:323-332.
13. Emberson JR, Kearney PM, Blackwell L, Newman C, Reith C, Bhala N, Holland L, Peto R, Keech A, Collins R, Simes J, Baigent C. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175, 000 people in 27 randomised trials of statin therapy. PLoS One 2012; 1:e29849.
14. McGlynn KA, Hagberg K, Chen J, Graubard BI, London WT, Jick S, Sahasrabuddhe VV. Statin use and risk of primary liver cancer in the Clinical Practice Research Datalink. J Natl Cancer Inst. 2015; 107. pii: djv009.
15. Bjorkhem-Bergman L, Backheden M, Soderberg LK. Statin treatment reduces the risk of hepatocellular carcinoma but not colon cancer-results from a nationwide case-control study in Sweden. Pharmacoepidemiol Drug Saf 2014; 10:1101-1106.
16. Lai SW, Liao KF, Lai HC, Muo CH, Sung FC, Chen PC. Statin use and risk of hepatocellular carcinoma. European Journal of Epidemiology 2013; 6:485-492.
17. El-Serag HB, Johnson ML, Hachem C, Morgana RO. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 2009; 5:1601-1608.
18. Tsan YT, Lee CH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. Journal of Clinical Oncology 2012; 6:623-630.
19. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med 2012; 19:1792-1802.
20. Boudreau DM, Yu O, Johnson J. Statin use and cancer risk: a comprehensive review. Expert Opinion on Drug Safety 2010; 4:603-621.
21. Gronich N, Rennert G. Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates. Nature Reviews Clinical Oncology 2013; 11:625-642.
22. Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends in Pharmacological Sciences 1998; 1:26-37.
23. Cao Z, Fan-Minogue H, Bellovin DI, Yevtodiyenko A, Arzeno J, Yang Q, Gambhir SS, Felsher DW. MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase. Cancer Research 2011; 6:2286-2297.
24. Ades AE, Sculpher M, Sutton A, Abrams K, Cooper N, Welton N, Lu G. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics 2006; 1:1-19.
25. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published metaanalyses. BMJ 2003; 7387:472.
26. Moher D, Liberati A, TetzlaffJ, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. International Journal of Surgery 2010; 5:336-341.
27. Wells GA. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses. Available from http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
28. Zhu GQ, Shi KQ, Huang S, Wang LR, Lin YQ, Huang GQ, Chen YP, Braddock M, Zheng MH. Systematic review with network meta-analysis: the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy. Aliment Pharmacol Ther 2015; 7:624-635.
29. Zhu GQ, Shi KQ, Huang S, Huang GQ, Lin YQ, Zhou ZR, Braddock M, Chen YP, Zheng MH. Network metaanalysis of randomized controlled trials: efficacy and safety of UDCA-based therapies in primary biliary cirrhosis. Medicine (Baltimore) 2015; 11:e609.
30. Zhu GQ, Shi KQ, Yu HJ, He SY, Braddock M, Zhou MT, Chen YP, Zheng MH. Optimal adjuvant therapy for resected hepatocellular carcinoma: a systematic review with network meta-analysis. Oncotarget 2015; 20:18151-18161 doi: 10.18632/oncotarget.4098.